Warf 5 Tablet contains Warfarin 5 mg, an oral anticoagulant used to prevent and treat thromboembolic disorders. Warfarin acts by inhibiting the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as proteins C and S, thereby reducing blood coagulation. It is primarily indicated for the prophylaxis and treatment of venous thrombosis, pulmonary embolism, atrial fibrillation with embolization risk, and prevention of stroke in patients with mechanical heart valves. Warf 5 Tablet requires careful dose titration and regular monitoring of the International Normalized Ratio (INR) to maintain therapeutic anticoagulation and minimize the risk of bleeding complications. Patients should be advised to maintain consistent dietary vitamin K intake and inform healthcare providers of any changes in medication, diet, or health status. Warfarin is contraindicated in patients with active bleeding, severe hypertension, pregnancy (due to teratogenicity), and known hypersensitivity to the drug. Common adverse effects include bleeding, bruising, and rarely, skin necrosis or purple toe syndrome. Warf 5 Tablet should be used under strict medical supervision with periodic laboratory assessments to ensure safety and efficacy. Patient education on adherence and recognition of bleeding signs is essential for optimal therapeutic outcomes.